Navigation Links
Phase III pivotal results presented of VYVANSE to treat ADHD in adults
Date:5/8/2008

WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints.

"Adults with ADHD often find it challenging to focus and organize during the day. The disorder may impact many aspects of their lives from career to family and personal commitments," said Lenard A. Adler, M.D., lead researcher in this study and director of the Adult ADHD program at the NYU Langone Medical Center, associate professor of psychiatry, neurology and child and adolescent psychiatry at the New York University School of Medicine, as well as author of Scattered Minds: Help and Hope for Adults with ADHD (G. P. Putnam's Sons 2006). "This study demonstrated that VYVANSE significantly improved ADHD symptoms in adults, including inattention, such as the ability to focus, organize and complete tasks, which are essential during an adult day, as well as hyperactivity, such as restlessness, and impulsivity."

This double-blind, placebo-controlled, four-week, forced-dose study in 414 adults aged 18 to 55 years showed that treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) provided a significant reduction in ADHD Rating Scale (ADHD-RS-IV) scores within one week that were observed throughout the full treatment period. At endpoint, VYVANSE demonstrated a significant improvement in ADHD symptoms, based on a 43 percent reduction in ADHD-RS scores. This is the largest placebo-controlled stimulant trial of ADHD in adults conducted to date.

Additional Study Findings Investigators also measured the efficacy of VYVANSE with the Clinical Global Impressions-Improvement (CGI-I) scale and found that the percentage of subjects taking VYVANSE rated "much improved" or "very much improved" was approximately 60 percent across all doses and was significantly greater than placebo.

The most commonly reported adverse events in this study were generally mild to moderate in severity and included decreased appetite, insomnia and dry mouth.

On April 23, 2008, Shire received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE for the treatment of ADHD in adults aged 18 to 55 years. The FDA approved VYVANSE for the treatment of ADHD in children aged 6 to 12 years on February 23, 2007.


'/>"/>

Contact: Lucia Lodato
lucia.lodato@porternovelli.com
917-617-3058
Porter Novelli
Source:Eurekalert

Related medicine news :

1. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
2. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
3. Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting
4. Wal-Mart Launches Phase Three of $4 Prescription Program
5. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
6. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
7. Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
8. QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension
9. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
10. Many Phase 3 Cancer Drug Trials Yield Effective Medicines
11. Cancer treatments in phase 3 trials successful up to half of the time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Tuesday, March 28, 2017, is the annual American Diabetes ... Risk Test to find out if they are at risk for developing Type 2 ... the evening sky by programming the LAX pylons the color red. Downtown’s U.S. Bank ...
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid Secret ... Wentz, Pharm.D., FASCP. The program was recently launched on March 1, and Dr. ... thyroid function. , Dr. Izabella Wentz is a licensed pharmacist and a ...
(Date:3/28/2017)... ... 2017 , ... Medforce Technologies, Inc., a leading provider of ... joined the National Association for Home Care and Hospice (NAHC), the largest and ... Americans of all ages and the caregiver who provide them with in-home health ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a leader in ... Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are the most ... kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way calling with ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017 Neurim Pharmaceuticals ("Neurim") ... obtain exclusive marketing rights for Neurim,s new Rx PedPRM in ... ... treat sleep disorders in children with Autism Spectrum Disorders (ASD) and ... approved for children. The collaboration with Exeltis will help ...
(Date:3/29/2017)... , March 29, 2017 ... Sectra (STO: SECT B) announces that ... install Sectra PACS in their healthcare enterprise. The ... Epic EMR, will enable access and sharing of ... Additionally, UPHS and Sectra will enter into a ...
(Date:3/28/2017)...  Las Vegas ophthalmology practice, Center For Sight, announced ... Dublin ), an implant that shunts ... intraocular pressure in patients with moderate to severe glaucoma. ... glaucoma that can lead to progressive optic nerve damage ... untreated. According to the National Eye Institute, ...
Breaking Medicine Technology: